Navigation Links
ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
Date:7/14/2008

- Conference Call to Discuss Results to Be Held at 9:00 A.M. -

EXTON, Pa., July 14 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) second quarter financial results for 2008 are expected to be released on Wednesday, July 30, 2008 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2008 second quarter financial results and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com. An audio archive will be available at the same address until August 15, 2008. To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin- resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses it
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. ViroPharma to Present at the Maxim Group First Annual Growth Conference
2. ViroPharma to Present at the UBS Global Life Sciences Conference
3. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
4. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
5. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
6. ViroPharma Augments Senior Management
7. ViroPharma Provides Update on Vancocin(R)
8. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
9. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
10. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
11. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... activity monitors hold great promise in helping people ... increasingly sophisticated devices help the wearers improve their ... responses. This information is organized into companion computer ... large and quickly growing market for these devices, ... at Galveston analyzed 13 of these activity monitors, ...
(Date:9/16/2014)... magnesium sulfate is routinely given to pregnant women at ... won,t provide any long-term benefits for infants. ... pregnant women, researchers in Australia found it had no ... those children when they were assessed at between 6 ... negate the fact that the drug is helpful in ...
(Date:9/16/2014)... therapy as part of breast conservation is the ... positive (HR+) invasive breast cancer. A new study ... shows that combination may not be necessary for ... The results, which Fox Chase researchers presented at ... Meeting on Sunday, September 14, suggest that low-risk ...
(Date:9/16/2014)... DC (PRWEB) September 16, 2014 Programs ... potentially yield hundreds of billions of dollars in savings ... report by the Commonwealth Fund. To help spur these ... seeking up to 10 collaborative groups from across the ... 1.0 ( http://bit.ly/1wo4gsa ) - a handbook designed to ...
(Date:9/16/2014)... 16, 2014 Who:, The Pulmonary Hypertension ... Campus and Children’s Hospital Colorado are hosting ... country’s leading pulmonary hypertension association that works to find ways ... of the lungs that affects the functioning of the heart ... survivability is only 2.8 years. , What:, Colorado PH ...
Breaking Medicine News(10 mins):Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3Health News:Researchers Don't See Long-Term Benefits From Drug for Preemies 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:NQF Seeks Field Testing Groups for Population Health Guide 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 3Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2
... EXTON, Pa., Feb. 13 Kensey Nash Corporation (Nasdaq: ... the Canaccord Adams Musculoskeletal Conference at the University ... 24, 2009.Douglas G. Evans, Kensey Nash,s Chief Operating Officer, ... p.m. (ET). The presentation materials will be available ...
... researcher explains , , FRIDAY, Feb. 13 (HealthDay News) -- ... "number sense," but it,s the use of language to ... much higher levels, says a Duke University expert. , ... at Duke, studies how human adults and infants, lemurs ...
... ATSI ), manufacturer and marketer of state-of-the-art cardiac ... financial results,for the fourth quarter ended December 31, 2008, ... The Company will host a conference call and,webcast on ... (2:00 p.m.,Pacific Time) to discuss its fourth quarter and ...
... following is from Betsy McCaughey, Ph.D., the author of the ... Plan."If Keith Olbermann of MSNBC could defend the ... he wouldn,t be resorting to personal attacks on me. ... (2-12-2009). That,s not true.I am not paid by the ...
... Facilities, especially teaching hospitals, have to do more to promote ... Most hospital patients cannot identify -- by name or role ... study of one urban hospital suggests. , "The majority of ... anybody in charge of their care," said study author Dr. ...
... asset to the global practice of radiologyBOSTON, Feb. ... ), a leader in radiology and medical image ... of Directors member Dr. Phillip Berman passed away ... lung cancer. Dr. Berman was 55 years old.(Logo: ...
Cached Medicine News:Health News:College Kids and Monkeys About Equal on Math 2Health News:ATS Medical Announces Fourth Quarter 2008 Earnings Release Date and Conference Call 2Health News:Invitation to Keith Olbermann 2Health News:Many Hospital Patients Can't ID Their Doctors 2Health News:Many Hospital Patients Can't ID Their Doctors 3Health News:AMICAS Mourns the Passing of Board Member Dr. Phillip Berman 2
(Date:9/16/2014)... Ind. , Sept. 16, 2014   Evana ... of custom, automated assembly and test systems, recently received ... a leading medical device manufacturer. The Evana solution will ... quality and ergonomics, as well as reduce labor. ... automatically fed to Evana,s robotic assembly cell. The robot ...
(Date:9/16/2014)... 16, 2014   Vestagen Technical Textiles, Inc. ... at hospitals. The myComfort™ line of patient apparel is ... that is fluid repellant, breathable and in studies done ... of bacteria on the fabric i . ... the chain of transmission. We want myComfort to be ...
(Date:9/16/2014)... OKLAHOMA CITY , Sept. 16, 2014 ... biopharmaceutical company developing novel orally active drugs ... existing antibiotics, announced today a $1.4 million ... investing arm of life sciences accelerator Accele ... from i2E, Inc., a nationally recognized private ...
Breaking Medicine Technology:Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 2Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 3New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4
... Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), a ... company will actively participate at the Save A Leg, ... in Orlando tomorrow, October 8. , In addition to exhibiting its ... a workshop entitled " The ...
... ACCESS PHARMACEUTICALS, INC . (OTC ... agreement with iMedicor (OTC Bulletin Board: VMCI) for the North ... rinse for the management of oral mucositis and stomatitis caused ... System application, initial introduction of MuGard to the 216,000 selected ...
Cached Medicine Technology:Wound Management to Participate at Save A Leg, Save a Life Foundation National Conference 2Wound Management to Participate at Save A Leg, Save a Life Foundation National Conference 3Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM) 2Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM) 3Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM) 4
... Multichannel, with it's streamlined design, ... routine laboratory tasks. The multichannel ... Soft-touch tip ejection, Super blow-out ... models), Entire pipette autoclavable, streamlined ...
... wide variety of applications. • Whole pipette is ... freely rotated against the handle to work in ... angle towards the microtiter plate. • The special ... common pipette tips, and provides a firm, parallel ...
... with 96-well plates in mind, Pipetman ... molecular biology applications: PCR* sequencing, immunology ... etc. Used with Diamond Tips from ... product will maximize performance and assure ...
... Multichannel, with it's streamlined design, ... routine laboratory tasks. The multichannel ... Soft-touch tip ejection, Super blow-out ... models), Entire pipette autoclavable, streamlined ...
Medicine Products: